|
1
|
Reid BM, Permuth JB and Sellers TA:
Epidemiology of ovarian cancer: A review. Cancer Biol Med. 14:9–32.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Basu P, De P, Mandal S, Ray K and Biswas
J: Study of ‘patterns of care’ of ovarian cancer patients in a
specialized cancer institute in Kolkata, eastern India. Indian J
Cancer. 46:28–33. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Desai A, Xu J, Aysola K, Qin Y, Okoli C,
Hariprasad R, Chinemerem U, Gates C, Reddy A, Danner O, et al:
Epithelial ovarian cancer: An overview. World J Transl Med. 3:1–8.
2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Vasey PA, Paul J, Birt A, Junor EJ, Reed
NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R, et
al: Docetaxel and cisplatin in combination as first-line
chemotherapy for advanced epithelial ovarian cancer. Scottish
gynaecological cancer trials group. J Clin Oncol. 17:2069–2080.
1999.PubMed/NCBI View Article : Google Scholar
|
|
7
|
McGuire WP, Hoskins WJ, Brady MF, Kucera
PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M:
Cyclophosphamide and cisplatin compared with paclitaxel and
cisplatin in patients with stage III and stage IV ovarian cancer. N
Engl J Med. 334:1–6. 1996.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Piccart MJ, Bertelsen K, James K, Cassidy
J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et
al: Randomized intergroup trial of cisplatin-paclitaxel versus
cisplatin-cyclophosphamide in women with advanced epithelial
ovarian cancer: Three-year results. J Natl Cancer Inst. 92:699–708.
2000.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Markman M, Kennedy A, Webster K, Peterson
G, Kulp B and Belinson J: Combination chemotherapy with carboplatin
and docetaxel in the treatment of cancers of the ovary and
fallopian tube and primary carcinoma of the peritoneum. J Clin
Oncol. 19:1901–1905. 2001.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dieras V, Guastalla JP, Ferrero JM, Cure
H, Weber B, Winckel P, Lortholary A, Mayer F, Paraiso D, Magherini
E and Pujade-Lauraine E: A multicenter phase II study of cisplatin
and docetaxel (Taxotere) in the first-line treatment of advanced
ovarian cancer: A GINECO study. Cancer Chemother Pharmacol.
53:489–495. 2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kavanagh JJ, Kudelka AP, de Leon CG,
Tresukosol D, Hord M, Finnegan MB, Kim EE, Varma D, Forman A, Cohen
P, et al: Phase II study of docetaxel in patients with epithelial
ovarian carcinoma refractory to platinum. Clin Cancer Res.
2:837–842. 1996.PubMed/NCBI
|
|
12
|
Ota T, Takeshima N and Takizawa K:
Second-line chemotherapy for carboplatin/paclitaxel-refractory
ovarian cancer: Are multi-agent chemotherapies of little value
truly? Eur J Gynaecol Oncol. 32:471–475. 2011.PubMed/NCBI
|
|
13
|
Strauss HG, Henze A, Teichmann A, Karbe I,
Baumgart A, Thomssen C and Koelbl H: Phase II trial of docetaxel
and carboplatin in recurrent platinum-sensitive ovarian, peritoneal
and tubal cancer. Gynecol Oncol. 104:612–616. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Benjapibal M, Kudelka AP, Vasuratna A,
Edwards CL, Verschraegen CF, Valero V, Vadhan-Raj S and Kavanagh
JJ: Docetaxel and cyclophosphamide induced remission in platinum
and paclitaxel refractory ovarian cancer. Anticancer Drugs.
9:577–579. 1998.PubMed/NCBI View Article : Google Scholar
|
|
15
|
ten Tije AJ, Verweij J, Loos WJ and
Sparreboom A: Pharmacological effects of formulation vehicles:
Implications for cancer chemotherapy. Clin Pharmacokinet.
42:665–685. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Coors EA, Seybold H, Merk HF and Mahler V:
Polysorbate 80 in medical products and nonimmunologic anaphylactoid
reactions. Ann Allergy Asthma Immunol. 95:593–599. 2005.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Schwartzberg LS and Navari RM: Safety of
polysorbate 80 in the oncology setting. Adv Ther. 35:754–767.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
FDA Drug Safety Communication (2014, June
20). FDA warns that cancer drug docetaxel may cause symptoms of
alcohol intoxication after treatment. Retrieved from: https://www.fda.gov/Drugs/DrugSafety/ucm401752.htm.
Accessed April 21, 2020.
|
|
19
|
Mirza A and Mithal N: Alcohol intoxication
with the new formulation of docetaxel. Clin Oncol (R Coll Radiol).
23:560–561. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Ahmad A, Sheikh S, Ali SM, Ahmad MU,
Paithankar M, Saptarishi D, Maheshwari K, Kumar K, Singh J and
Patel G: Development of aqueous based formulation of docetaxel:
Safety and pharmacokinetics in patients with advanced solid tumors.
J Nanomed Nanotechnol. 6:2015.
|
|
21
|
Lewis LD, Miller AA, Rosner GL, Dowell JE,
Valdivieso M, Relling MV, Egorin MJ, Bies RR, Hollis DR, Levine EG,
et al: A comparison of the pharmacokinetics and pharmacodynamics of
docetaxel between African-American and Caucasian cancer patients:
CALGB 9871. Clin Cancer Res. 13:3302–3311. 2007.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ahmad A, Sheikh S, Taran R, Srivastav SP,
Prasad K, Rajappa SJ, Kumar V, Gopichand M, Paithankar M, Sharma M,
et al: Therapeutic efficacy of a novel nanosomal docetaxel lipid
suspension compared with taxotere in locally advanced or metastatic
breast cancer patients. Clin Breast Cancer. 14:177–181.
2014.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Ashraf M, Sajjad R, Khan MA, Shah M, Bhat
Y and Wani ZA: 1046-Efficacy and safety of a novel nanosomal
docetaxel lipid suspension (NDLS) as an anti cancer agent-a
retrospective study. Ann Oncol. 27 (Suppl 9):ix46–ix51. 2016.
|
|
24
|
Naik R and Khan MA: Doceaqualip in a
patient with prostate cancer who had an allergic reaction to
conventional docetaxel: A case report. Mol Clin Oncol. 6:341–343.
2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Prasanna R, Bunger D and Khan MA: Efficacy
and safety of DoceAqualip in a patient with locally advanced
cervical cancer: A case report. Mol Clin Oncol. 8:296–299.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vyas V, Joshi N and Khan MA: Novel
docetaxel formulation (NDLS) in low cardiac reserve ovarian cancer.
Open Access J Cancer Oncol. 2(000122)2018.
|
|
27
|
Gupta S, Pawar SS and Bunger D: Successful
downstaging of locally recurrent penile squamous cell carcinoma
with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based
regimen followed by curative surgery. BMJ Case Rep: Nov 12, 2017
(Epub ahead of print). doi: 10.1136/bcr-2017-220686.
|
|
28
|
Ashraf QM, Sajad QR, Khan MA, Wani ZA,
Mujeeb S, Bhat YM and Joshi N: Efficacy and safety of a novel
nanosomal docetaxel lipid suspension as an anticancer-A
retrospective study. J Cancer Oncol. 2(000132)2018.
|
|
29
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009.PubMed/NCBI View Article : Google Scholar
|
|
30
|
National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines in Oncology (NCCN
Guidelines®). Ovarian cancer including fallopian tube
cancer and primary peritoneal cancer. Version 2.2020-January 12,
2021. [cited 25 Feb 2021]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
|
|
31
|
Vasey PA, Atkinson R, Coleman R, Crawford
M, Cruickshank M, Eggleton P, Fleming D, Graham J, Parkin D, Paul
J, et al: Docetaxel-carboplatin as first line chemotherapy for
epithelial ovarian cancer. Br J Cancer. 84:170–178. 2001.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Mokhlesuddin M, Akhter PS, Ahmed DU, Khan
MA, Rahman MA and Islam T: Clinical experience of using
docetaxel-cisplatin in the treatment of advanced ovarian cancer: A
Bangladesh perspective. J Clin Oncol. 24 (Suppl
18)(S15070)2006.
|
|
33
|
Vasey PA, Atkinson R, Osborne R, Parkin D,
Symonds R, Paul J, Lewsley L, Coleman R, Reed NS, Kaye S and Rustin
GJ: SCOTROC 2A: Carboplatin followed by docetaxel or
docetaxel-gemcitabine as first-line chemotherapy for ovarian
cancer. Br J Cancer. 94:62–68. 2006.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Katsumata N: Docetaxel: An alternative
taxane in ovarian cancer. Br J Cancer. 89 (Suppl 3):S9–S15.
2003.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Weiss RB, Donehower RC, Wiernik PH, Ohnuma
T, Gralla RJ, Trump DL, Baker JR Jr, Van Echo DA, Von Hoff DD and
Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin
Oncol. 8:1263–1268. 1990.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Herzog TJ, Monk BJ, Rose PG, Braly P,
Hines JF, Bell MC, Wenham RM, Secord AA, Roman LD, Einstein MH, et
al: A phase II trial of oxaliplatin, docetaxel, and bevacizumab as
first-line therapy of advanced cancer of the ovary, peritoneum, and
fallopian tube. Gynecol Oncol. 132:517–525. 2014.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Obradović MMS, Hamelin B, Manevski N,
Couto JP, Sethi A, Coissieux MM, Münst S, Okamoto R, Kohler H,
Schmidt A and Bentires-Alj M: Glucocorticoids promote breast cancer
metastasis. Nature. 567:540–544. 2019.PubMed/NCBI View Article : Google Scholar
|
